Johnson & Johnson unveiled its second atopic dermatitis-focused deal this month on 28 May, paying $1.25bn in cash to acquire a subsidiary of Numab Therapeutics AG that houses a Phase II-ready bispecific antibody that J&J thinks will offer a novel approach to addressing two distinct disease-driving pathways in AD.
Key Takeaways
-
Johnson & Johnson is paying $1.25bn for Numab’s IL-4Rα and IL-31-targeted bispecific for development in atopic dermatitis.
The agreement follows J&J’s 16 May deal to acquire privately held Proteologix for $850m, driven by preclinical PTX128, an antibody...